Background: Treatment options for poorly differentiated (PDTc) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising.

Materials and Methods: Primary ATC (n=93) and PDTc (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR mRNA was quantified in 31 ATC and 14 PDTc with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable.

Results: PD-L1 TPS ≥ 50% was observed in 42% of ATC and 26% of PDTc specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTc (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTc samples had PD-L1 expression ≤ 5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTc and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS.
INTRODUCTION

Anaplastic (ATC) and poorly differentiated thyroid carcinoma (PDTC) are orphan diseases which account for 1-2% and 2-15% % among all thyroid malignancies (1, 2). While treatment of DTC is well established and 5-year survival rates are above 90% (3), the management of PDTC and ATC is unsatisfactory and prognosis generally poor with a median overall survival of only six months for ATC patients (4, 5). Current guidelines recommend surgery in ATC cases (stage IVA and IVB) and a careful evaluation of surgical options in stage IVC cases (6). Surgery can be followed by additive chemoradiation therapy to improve locoregional control and overall outcome (7, 8). Nonsurgical treatment options include chemotherapy, palliative radiotherapy, systemic therapy or best supportive care (6). The combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib for BRAF V600E-mutated ATC poses a recent breakthrough with an overall response rate of 69% (9, 10). For stage IVC non-BRAF V600E-mutated cases guidelines recommend evaluation of PD-L1 status and treatment with checkpoint inhibitors as an alternative to chemotherapy and/or radiation (6). The prognosis of PDTC is more favorable with a 5-year survival rate of 66% because some PDTC are accessible to radioiodine treatment (11, 12). Secondary resistance to radioiodine therapy limit a curative approach in advanced cases (13). Lenvatinib (LEN) is a multi-tyrosine kinase inhibitor (TKI) of VEGFR1-3, FGFR1-4, PDGFR, RET and c-kit and approved for thyroid carcinomas refractory to radioiodine share common, e.g., antiangiogenetic TKI activity it has been speculated that the superior clinical response of LEN in these rare thyroid carcinomas may be attributable to its ability to also target FGFR 1-4 (19).

A study that used immunohistochemistry to investigate FGFR4 expression in 12 ATC patients suggested that FGFR4 expression may predict response to LEN (20).

The immune checkpoint inhibitor (ICI) pembrolizumab (PEM) is a programmed death 1 (PD-1) inhibitor approved for numerous types of cancer such as non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and head and neck squamous cell cancer (HNSCC) (21–24). Tumoral tissue expression of its ligand PD-L1 as assessed by immunohistochemistry has been proposed as a biomarker and for some tumor entities disease-specific cut-offs have been suggested (25). As part of a phase I/II study 42 ATC patients were treated with PD-1 inhibitor spartalizumab and showed higher response rates in PD-L1-positive versus PD-L1 negative ATC patients with highest rate of response in patients with PD-L1 ≥ 50% (26). In ATC, a phase II trial of single agent PEM or a combination with chemoradiotherapy was prematurely terminated due to rapid fatal outcome in the three patients investigated (27). Trials in multiple disease entities are ongoing including a trial in patients with radioiodine refractory thyroid carcinoma without prior TKI treatment from which preliminary positive results have been reported (NCT02973997).

Addition of PEM after prior failure to TKI therapy with LEN, dabrafenib alone or in combination with trametinib has been reported in a retrospective single center study. Partial response (PR) was seen in 43% but with a very short median PFS of 3 months and a median overall survival (OS) of 7 months only (8). In a recent series of metastatic ATC and PDTC negative for the BRAF V600E mutation, 8 patients received a combination therapy of LEN and PEM for a maximum of 40 months after failing chemotherapy, radiation or radioiodine therapy. The combination treatment was not only well tolerated with 50% (3/6) of ATC patients still on therapy at data cutoff but also led to complete response (CR) in 66% (4/6) of ATC patients after 7, 10 and 12 months and PR in 75% of patients after three to four months of treatment (28). Range of PD-L1 expression was 1%-90% and patients with a PD-L1 expression greater than 50% (5/8) responded best to combination therapy (28). There was no association of PD-1 expression or frequency of tumor infiltrating lymphocytes (TILs) with treatment response (28).

The primary aim of this study is to evaluate a potential molecular rationale for a treatment of ATC and PDTC patients with lenvatinib, pembrolizumab or a combination of both. Secondary aims were the investigation of FGFR and PD-L1 expression as prognostic markers and potential marker of treatment response. As an exploratory aim, we describe the

Conclusion: High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.

Keywords: tyrosine kinase inhibitor (TKI), immune checkpoint inhibitor (ICI), immunohistochemistry, immunotherapy, PD-L1, FGFR

Adam et al. FGFRs/PD-L1 in ATC and PDTC
clinical benefit of patients treated with these substances as a monotherapy or in a combined regimen.

**MATERIALS AND METHODS**

**Setting**

This study was conducted as part of the German Study Group for rare malignant tumors of the thyroid and parathyroid glands. The study was approved by the ethics committee of the University of Würzburg (96/13) and subsequently by the ethics committees of all participating centers. All patients provided written informed consent. Prospectively and retrospectively collected data and formalin-fixed paraffin embedded (FFPE) tissue samples of patients diagnosed with ATC and PDTC between 1997 and 2019 were obtained from five German tertiary care centers.

**Samples and Data Acquisition**

Adult patients with local diagnosis of ATC or PDTC at histopathologic examination of sections or biopsy of the primary tumor were eligible. Archival anonymized papillary thyroid carcinoma (PTC) and normal thyroid (NT) tissue from the institute of pathology, University of Würzburg, served as control.

Clinical data such as the date of diagnosis, tumor stage at initial diagnosis, treatments including surgical interventions, radioiodine treatment and systemic therapies (e.g., cytotoxic chemotherapy, radiotherapy, TKI- and/or ICI-therapy), metastatic sites and number of treatment lines, were recorded by trained personnel at all sites. Tumor stage was recorded according to UICC classification (TNM Classification of Malignant Tumours, 8th edition, 2017) and determined for PDTC and ATC respectively.

Study endpoints were disease-related death or time interval from diagnosis to last follow-up alive. Treatment and follow-up of patients was done according to standard of care at participating centers.

**Histopathological Review**

The diagnosis of ATC and PDTC in archival FFPE tissue samples (n=140) was verified by a single endocrine pathologist (SK). According to the current WHO Classification of Tumours of Endocrine organs (4th edition, volume 10, 2017).

**Immunohistochemistry**

All specimens were processed by immunohistochemistry and RNAscope® in situ hybridization within two weeks after sectioning. Full FFPE sections of primary tumor tissue (n=93 ATC; n=47 PDTC) mounted on slides were deparaffinized, rehydrated and antigen retrieval was performed in target retrieval solution (Target Retrieval Solution, Citrate pH 6.1 [10x], Dako, CA, USA; 1:10 dilution) under pressure for 4 minutes. Following deparaffinization, steps were carried out with a Freedom EVO 200 base unit (TECAN Trading AG, Switzerland). Tissue sections were incubated with primary antibody (PD-L1 [28-8] rabbit monoclonal antibody 438R-15-ASR; Cell Marque, CA, USA; 1:100 dilution; Antibody Diluent, Dako REAL) for 1h at RT. Signal amplification was achieved by the HRP Kit (HPR HiDef 2-Step Polymer Detection Kit, medac GmbH, Germany) for 40 min and developed for 10 min with Histofine (Histofine DAB-2V, Nichirei Biosciences Inc., Japan). Nuclei were counterstained using Mayer’s hematoxylin for 3 min and blued for 10 min in running tap water. Following dehydration, slides were mounted by a Tissue-Tek (Sakura Finetek, Inc., CA, USA).

**RNAscope In Situ Hybridization**

Given the limited reliability of immunohistochemistry for FGFRs due to their high degree of homology, RNAscope was used to study expression of FGFR 1-4. Tumor samples (ATC: n=31; PDTC: n=14) were cut to 2-μm thickness, deparaffinized in xylene, and rehydrated in a graded alcohol series. Fixation, permeabilization and protease digestion were achieved by treatment with hydrogen peroxide (322335, Advanced Cell Diagnostics [ACDbio], CA, USA) at RT for 10 min, target retrieval reagent (322000, ACDbio) under pressure for 15 min and protease plus (322331, ACDbio) at 40°C for 20 min. FGFR 1-4 probes (Hs-FGFR1, 310071; Hs-FGFR2, 311171; Hs-FGFR3, 310791; Hs-FGFR4-CD5, 412301, ACDbio) were then hybridized at 40°C for 2h. Slides were treated with Amplifier 1 (322311, ACDbio) and Amplifier 3 (22313, ACDbio) at 40°C for 45 min, with Amplifier 2 (322312, ACDbio) and Amplifier 4 (322314, ACDbio) at 40°C for 20 min, and with Amplifier 5 (322315, ACDbio) for 1h and Amplifier 6 (322316, ACDbio) for 20 min at RT. In between the amplification steps, slides were washed in wash buffer (310091, ACDbio) for 4 min, each. Equal volumes of DAB-A (DAB-A, 320052, ACDbio) and DAB-B (DAB-B, 320053, ACDbio) were mixed and pipetted on the slides. After incubation at RT for 10 minutes slides were put in hematoxylin, dehydrated and mounted.

**Semi-Quantitative Analysis of PD-L1 and FGFR 1-4 Expression**

PD-L1 slides were visually scored using an AxioScope.A1 microscope (Carl Zeiss AG, Germany). PD-L1 expression was evaluated using a semi-quantitative scoring system based on the proportion of stained tumor cells according to Tumor Proportion Score (TPS).

FGFR1-4 images were assessed with Aperio VERSA microscope (Leica Biosystems, Germany). Manual counting of cell nuclei and RNA was performed with ImageJ-win64 (Fiji, GitHub enterprise, CA, USA), and quantified as the number of FGFR 1-4 mRNA per cell.

**Statistical Analysis**

DSS from diagnosis was estimated using the Kaplan-Meier method and groups were compared by the log-rank test. For data with non-normal distribution we used Mann-Whitney
U test. Kruskal-Wallis test was used for comparison among groups for non-nominal distributed variables. Assessment of risk factors was performed by using the Cox proportional hazard regression model (forward and backward step-up regression). P values <0.05 were considered statistically significant. Statistical analyses were performed with SPSS Version 26 (IBM, Chicago, IL, USA). GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA) and Microsoft Office Excel 2010 were used for graphical presentation and additional analyses.

RESULTS

Clinical Characteristics

93 patients (40 male, 53 female) with histological evidence of ATC and 47 patients (17 male, 30 female) with poorly differentiated thyroid carcinoma treated at five German tertiary care centers were included. Baseline clinical characteristics of the study population are shown in Table 1. In brief, median age at primary diagnosis of ATC patients was 69 years (range 29-95) and 63 years (range 16-86) for patients with PDTC. At the time of initial diagnosis 47 patients with ATC (51%) and 13 patients with PDTC (28%) had local regional lymph node metastases. Disease was restricted to the thyroid gland (stage IVA) at diagnosis in one single ATC patient whereas 52% had distant metastasis (stage IVC). 15 PDTC patients had distant metastases at first diagnosis, four of whom were <55 years (UICC stage II) and 11 aged ≥55 years (UICC stage IVB).

Expression of PD-L1 in ATC and PDTC

The proportion of PD-L1 expression in tumor cells differed widely both in ATC and PDTC samples (Figure 1) and was heterogeneous within samples which is accounted for in the semiquantitative TPS. Median PD-L1 TPS was 30% (range 0-95) in ATC (n=93) compared to 5% (range 0-95) in PDTC (n=47, p<0.01, Figure 2) and was significantly higher in ATC (p<0.0001) and PDTC (p<0.001) compared to normal thyroid tissue samples (n=30). 39 (42%) of ATC samples and 12 (26%) of PDTC specimens expressed PD-L1 in ≥50% of tumor cells, while none of the PTC samples showed PD-L1 TPS of ≥50%. 27% of ATC samples and 53% of PDTC samples had PD-L1 TPS ≤5%. PD-L1 expression could not be detected in normal thyroid tissue (n=30). Differentiated PTC specimens (n=21) showed median PD-L1 expression of 10% (range 0-30).

Expression of FGFR 1-4 in ATC and PDTC

Expression of FGFR mRNA was generally low in all investigated samples (Figure 3). Median expression of FGFR 1 was 1.06 (range 0.16-5.42) mRNA/cell for ATC (n=31) tissue, 0.81 (range 0.18-1.87) mRNA/cell for PDTC (n=14) specimens, and 0.5 (range 0.15-0.97) mRNA/cell for PTC (n=5) tissue (Figure 4). Data on FGFR 2 and 3 are shown in Table 2. FGFR 4 exhibited the lowest median expression in all types of thyroid carcinoma (ATC: 0.14 mRNA/cell; PDTC: 0.24 mRNA/cell; PTC: 0.08 mRNA/cell). In comparison to normal thyroid tissue, panFGFR expression (sum of FGFR1–4) was significantly higher in ATC (p<0.01) and PDTC (p<0.0001) tissue (Figure 4). Median panFGFR expression was 2 mRNAs/cell in ATC and 3 mRNAs/cell in PDTC tissue. Normal thyroid tissue (n=8) expressed FGFR 1-4 at lowest levels with median expression of 0.0 mRNA/cell, respectively. FGFR 1-4 expression was not significantly different between ATC/PDTC and PTC tissue specimens.

Disease-Specific Survival and Tumor-Specific Therapy

83 patients (89%) died due to ATC, 3 (3%) patients with ATC deceased due to causes other than ATC and 7 (8%) patients were still alive at last follow-up. 14 PDTC patients (30%) died from advanced PDTC. In 2 PDTC patients the cause of death was unknown and 31 (66%) were still alive at last follow-up. In 4 (4%) ATC and 4 (9%) PDTC patients, there was no evidence of disease at last follow-up indicating complete remission. Median overall survival was 6.4 months for patients diagnosed with ATC and...
29.1 months for patients diagnosed with PDTC. Disease-specific survival was 5.4 (ATC) and 24.0 months (PDTC) in a median follow-up of 6 (ATC) and 28 (PDTC) months.

**Therapy With TKI and/or ICI**

Tumor-specific therapy was consistent with previous publications on ATC (4) and is summarized in Table 3. Targeted therapies with tyrosine kinase inhibitors (TKI) and/or immune checkpoint inhibitors (ICI) were administered in 15 (16%) of ATC and 13 (28%) of PDTC patients. Patients were treated with LEN (n=3 ATC, n=9 PDTC), PEM (n=2 ATC, n=1 PDTC), LEN + PEM (n=1 ATC, n=2 PDTC) and other TKIs (n=10 ATC; n=8 PDTC). Two PDTC patients received three different lines of targeted therapy, another two PDTC patients were treated with two different TKIs (LEN followed by sorafenib and LEN followed by cabozantinib), and one ATC and one PDTC patient received two lines of targeted therapy.

ATC patient #1 (TPS: 10%, panFGFR expression: 2.8 mRNA/cell) patient received LEN (dose varying from 8 mg to 14 mg) after failure of RCT with partial remission (PR) as best overall response (BOR). LEN monotherapy was followed by LEN and PEM combination therapy (doses 4 mg and 200 mg respectively) with stable disease (SD) as BOR (PFS until after last-follow-up: 9.9 months).

**FIGURE 1** | Representative PD-L1 immunohistochemistry staining of full ATC FFPE sections. Three different tissue samples stained with PD-L1 antibody are shown with an overview of the tissue sample (A, D, G; scale bars: 1mm), at 2x magnification (B, E, H; scale bars: 500μm) and 10x magnification (C, F, I; scale bars: 100μm). The PD-L1 TPS in (A–C) is 1% and 50% in D-F while 95% in (G–I).

**FIGURE 2** | Comparison of PD-L1 expression in ATC or PDTC and PTC or NT. (A) PD-L1 expression as assessed by TPS was significantly higher in ATC compared to PDTC and tumor specimens compared to normal thyroid (NT). No significant differences (n. s. = not significant) could be observed in ATC and PTC and PDTC and PTC. (B) Proportion of PD-L1 TPS categories in PDTC and ATC. 42% of ATC and 26% of PDTC specimen show PD-L1 TPS ≥50%. *p < 0.01, **p < 0.001, ***p < 0.0001.
ATC patient #2 (TPS: 10%) experienced SD by PEM monotherapy (dose: 200 mg every 3 weeks) with a PFS of 22.4 months. PEM treatment was followed by a combination of paclitaxel (80 mg every week) and PEM for 3.0 months. The patient deceased one month after termination of treatment.

ATC patient #3 (TPS: 1%, panFGFR expression: 1.0 mRNA/cell) consecutively received LEN and PEM as single agents each with PD as BOR. The PFS for LEN and PEM treatment was 1.7 and 2.3 months, respectively.

In a fourth ATC patient (TPS: 95%, panFGFR expression: 3.1 mRNA/cell), treatment with LEN and PEM was started after failure of RCT five days before the patient deceased and hence is considered unevaluable.

ATC patient #5 (TPS: 70%, panFGFR expression: 1.0 mRNA/cell) received LEN (dose: 24 mg) after failure of RCT with a PFS of 4.4 months with PD as BOR.

PDTC patient #6 (TPS: 50%, panFGFR expression not available) who was radioiodine refractory at diagnosis received LEN combined to PEM as first line treatment. Best response was SD and the patient received this combination for 21.5 months until progression occurred. Treatment was then switched to LEN and everolimus.

PDTC patient #7 (TPS: 30%, panFGFR expression 2.83 mRNA/cell) was treated with LEN, best response was SD and PFS 13.7 months. Everolimus was added to the therapy which resulted in SD for 9.7 months. Later, PEM was added to everolimus and LEN with PD after 1.8 months. The patient was still alive at last follow-up.

In a third (#8) PDTC patient (TPS: 90%, panFGFR expression not available) treatment was started with PEM as part of a clinical trial (Keynote 158) and discontinued 4 months later due to PD. Outside of the study, the patient received LEN and is...
still alive with SD as BOR after data cut-off (PFS until after last follow-up: 38.6 months).

PDTC patient #9 (TPS: 50%, panFGFR expression: 3.1 mRNA/cell) first received LEN (dose: 10 mg) with PR as BOR and PFS of 7.6 months followed by sorafenib (400 mg) for 3.0 months. Treatment was continued with LEN and PEM combination therapy with PR as BOR and a PFS of 6.6 months. Later the patient continued treatment with PEM monotherapy for 2.8 months.

PDTC patient #10 (TPS: 1%, panFGFR expression: 2.6 mRNA/cell) first received LEN (max. dose: 20 mg) with mixed response (MR) as BOR. Treatment was terminated due to adverse events with PFS of 5.7 months. LEN treatment was then followed by sorafenib (dose: 800 mg) for 1.7 months which was followed by chemotherapy.

Primary LEN monotherapy (max. dose: 14 mg) was also administered to PDTC patient #11 (TPS: 1%, panFGFR expression: 4.5 mRNA/cell) for 26.1 months. PEM was added shortly after imaging showed PD, but the patient deceased one month later.

The PFS and treatment response of the different patients treated with PEM alone in combination with LEN is depicted in Figure 5. Patients with moderate or high expression showed longer PFS.

Four additional PDTC patients were treated with LEN monotherapy. One patient (TPS: 5%, panFGFR expression: 2.1 mRNA/cell) received LEN 24 mg (PFS: 10.5 months) with SD followed by cabozantinib. Another patient (TPS: 80%) received LEN (max. dose: 24 mg) after RCT treatment, but deceased one month after initiation. A third patient (TPS: 10%) was treated with LEN for 8.9 months and died 8 days later and a fourth patient (TPS: 10%) received LEN (max. dose: 24 mg) for 19.7 months at last follow-up after data cut-off and is still alive with SD.

**Prognostic Factors of Disease Specific Survival in ATC and PDTC**

The association of clinical factors with DSS in ATC and PDTC is summarized in Table 4, respectively. In PDTC where prognostic factors are ill described, UICC stage I, II or III compared to IV, and use of RIT were associated with a significantly longer DSS. Treatment with external beam radiation therapy (EBRT) or

| Therapeutic regimen | No. of patients ATC (%) | No. of patients PDTC (%) |
|---------------------|-------------------------|--------------------------|
| Primary surgery     |                         |                          |
| One-stage thyroidectomy | 39 (42)                | 21 (45)                  |
| Two-stage thyroidectomy | 7 (8)                  | 12 (28)                  |
| Hernithyroidectomy   | 21 (23)                 | 9 (19)                   |
| debulking surgery    | 13 (14)                 | 0 (0)                    |
| biopsy               | 8 (9)                   | 0 (0)                    |
| only explorative surgery | 5 (5)               | 3 (6)                    |
| Not reported         | 0 (0)                   | 2 (4)                    |
| Resection status     |                         |                          |
| R0                   | 11 (12)                 | 25 (53)                  |
| R1                   | 37 (40)                 | 10 (21)                  |
| R2                   | 34 (37)                 | 2 (4)                    |
| Rx                   | 11 (12)                 | 10 (21)                  |
| Radiiodine treatment (RIT) | 6 (7)              | 36 (77)                  |
| Median number of RIT (range) | 1 (1-1)        | 1 (1-11)                 |
| Median cum. Dose (GBq) (range) | 3.36 (2.7-7.4) | 6.66 (1.2-7.4,2)        |
| Dose not available   | 1 (1)                   | 0 (0)                    |
| Radiochemotherapy (RCT) | 38 (42)              | 4 (9)                    |
| not available        | 2 (2)                   | 0 (0)                    |
| External beam radiation |                    |                          |
| Neck region          | 79 (85)                 | 16 (34)                  |
| Local palliative     | 52 (56)                 | 7 (15)                   |
| Median cum. Dose (Gy) (range) | 55.0 (4-105.6) | 60.5 (50.4-120)         |
| Dose not available   | 6 (7)                   | 1 (2)                    |
| Distant metastases   | 17 (18)                 | 12 (28)                  |
| Chemotherapy*        | 48 (53)                 | 6 (13)                   |
| Not reported         | 2 (2)                   | 0 (0)                    |
| Doxorubicin weekly   | 10 (11)                 | 1 (2)                    |
| Paclitaxel weekly    | 8 (9)                   | 0 (0)                    |
| Cisplatin            | 3 (3)                   | 0 (0)                    |
| Paclitaxel + carboplatin | 22 (24)           | 5 (11)                   |
| Paclitaxel + pemetrexed | 6 (7)                | 2 (4)                    |
| Doxorubicin based*   | 10 (11)                 | 0 (0)                    |
| Other                | 4 (4)                   | 0 (0)                    |
| unknown              | 2 (2)                   | 0 (0)                    |
| More than one chemotherapeutic regimen | 13 (14)     | 2 (4)                    |
| Tyrosine kinase inhibitor (TKI) and/or immune checkpoint inhibitor (ICI) therapy | 15 (16) | 13 (28) |
| Lenvatinib           | 3 (3)                   | 9 (19)                   |
| Pembrolizumab        | 2 (2)                   | 1 (2)                    |
| Lenvatinib + pembrolizumab | 1 (1)            | 2 (4)                    |
| Other*               | 10 (11)                 | 8 (17)                   |
| more than one therapy | 1 (1)                  | 5 (11)                   |

*Chemotherapy other than monotherapy with doxorubicin weekly.

*Vemurafenib, Sunitinib, Cabozantinib, Pazopanib, Imatinib, Nivolumab.
chemotherapy was associated with a significantly longer DSS in ATC while the opposite was observed in PDTC, where the use of EBRT and chemotherapy most likely indicate aggressive clinical course.

Considering PD-L1 TPS ≤ 5% as low, 6-49% intermediate and 50-100% as high expression, we did not observe significant differences of DSS among patients with ATC (p=0.495) or PDTC (p=0.496) patients (Figure 6). Using established cut-offs associated with response to PEM in NSCLC (scores from 0-49%: low; scores from 50-100%: high) no significant differences in DSS were observed as well (Supplementary Figure 1). We likewise did not find a prognostic relevance of FGFR1-4 expression for DSS (Supplementary Figure 2).

DISCUSSION

In this large multicenter analysis of prospectively and retrospectively collected clinical data and tissue specimens we systematically investigated the expression of the immune checkpoint molecule PD-L1 in the orphan diseases PDTC and ATC. We found variable expression in both types of aggressive thyroid malignancies with a significantly higher expression in ATC vs. PDTC. Importantly, while more than half of the PDTC samples showed a TPS below 5%, only 21% of ATC had PD-L1 below that arbitrary threshold. Of note, TPS of at least 1% was observed in all PDTC and ATC. In normal thyroid tissue, PD-L1 was absent but it was present at low levels in differentiated papillary thyroid carcinoma.

While clinical observations and small published studies suggested the expression of PD-L1 in the majority of ATC, we are not aware of a similarly large study on this topic (29, 30). Further strengths of our analysis are the systematic staining and evaluation at a single institution by a specialized endocrine pathologist and the systematic verification of diagnoses which is not the case in other series or was not reported (8). Overall, the presence of high PD-L1 expression in a substantial proportion of ATC and PDTC indicates a rationale for treatment with immune checkpoint inhibitors targeting the PD-1/PD-L1 axis. Our study is unable to support, however, a specific cut-off that would govern treatment with immune checkpoint inhibitors such as PEM. The TPS has been established as a response marker primarily for non-small cell lung cancer (NSCLC) and treatment of squamous cell head and neck cancer. In a retrospective analysis of ATC patients treated with kinase inhibitors and PEM progressive disease was observed in patients with PD-L1 TPS of 5%, 30% and 80% while a partial response was demonstrated in five patients, four of whom had PD-L1 TPS available with scores of >95%, 90%, 20% and >10% (8). Our data showed higher median PD-L1 expression in PTC than in PDTC (TPS 30% and 5% respectively), but range of PD-L1 expression in PDTC was much broader compared to PTC samples. PD-L1 expression has been reported for PTC tissue with and without lymphoid thyroiditis. PTC specimens with lymphoid thyroiditis showed higher expression of PD-L1 (39,1%) in comparison to PTC tissue without lymphoid thyroiditis (6,9%) (31). A review on the expression of PD-L1 in PTC tissue demonstrated significant association of PD-L1 expression with reduced disease-free survival (DFS), but not OS (32). We did not find any impact of PD-L1 expression on DSS. This is not surprising since the vast majority of patients did not receive PD-1/PD-L1 directed therapy. Hence, PD-L1 is not a prognostic marker but possibly a marker of treatment response in ATC and PDTC. Accordingly, a recently published ATC cohort from a phase I/II trial treated with spartalizumab, a PD-1 inhibitor, demonstrated objective response exclusively in patients with detectable PD-L1 expression (26). Guidelines recommend the evaluation of PD-L1 status in stage IVC ATC cases with lack of BRAF V600E mutation (6). Detection of high PD-L1 expression can be followed by treatment with immune checkpoint inhibitors and can be an alternative to chemotherapy and/or radiation (6).
The rationale to combine PD-L1 with LEN is supported by preclinical observations in an immunocompetent mouse model (33). The authors demonstrated profound changes of the immune microenvironment: LEN led to a pronounced increase in tumor-infiltrating immune cells, tumor-associated macrophages but also a pronounced increase of peripheral and tumoral polymorphonuclear myeloid derived suppressor cells (PMN-MDSC). The authors concluded that LEN exerts both pro-inflammatory and anti-inflammatory immune effects. By experimentally reducing the number of immunosuppressive PMN-MDSC the authors showed increased antitumoral efficacy of LEN alone and inhibition of the PD-1/PD-L1 axis was likewise associated with a decrease of immunosuppressive cell types. There is currently limited evidence of a direct immunomodulatory effect of LEN. Given the poor clinical response of ATC to VEGFR-directed TKI such as sorafenib, pazopanib and sunitinib, we reasoned that expression of the LEN targets FGFR1-4 on tumor cells may contribute to the specific antitumoral response of LEN monotherapy and in combination with immune checkpoint inhibitors. While immunohistochemistry of FGFR4 only has been used in one series (20) we consider our approach with RNAscope® in situ hybridization more reliable because it is not susceptible to cross-reactivity of FGFR antibodies in immunohistochemistry and permits the quantification of individual FGFRs. We found extremely low expression of all FGFR in the samples studied. FGFR1 was expressed at highest levels in PDTC and ATC compared to normal thyroid and PTC samples. Overall, we found significantly higher expression of the combination of FGFR1-4 in PDTC and ATC compared to normal thyroid but not to PTC. Tumor infiltrating leukocytes did not express FGFR1-4. Although we cannot exclude that the low expression of FGFR1-4 is still biologically relevant, we conclude that tumoral FGFRs are unlikely to be involved in the immunostimulatory action of LEN.

Our study of PD-L1 and FGFR1-4 expression in ATC and PDTC has some limitations: First, our study is – in part - retrospective in nature. Thus, selection bias confounds the association of treatment factors with prognosis and is the cause of the shorter DSS in PDTC patients receiving chemotherapy or EBRT. On the other hand, radioiodine positive PDTC have an inherently better prognosis.

Second, only few patients were treated with LEN or PEM (12 and 3 respectively) and even fewer patients were primarily treated with a combined regimen (n=3). It is therefore impossible to define cut-off values of response. Third, the tumor mutational burden and the LEN targets c-kit, RET, VEGFR 1-3 or PDGFR-α were not analyzed because we considered FGFR as the most relevant drug-specific target molecules. Indeed it has been suggested that beyond the actual tumoral angiogenesis, patient factors may contribute to the antitumoral effects observed with multi-kinase inhibitors such as LEN but also sorafenib (34, 35).

Finally, although relatively large for the rarity of the disease, the number of PDTC patients is still limited and no specific selection of PDTCs refractory to RIT was applied.

Together with the available preclinical data, our findings suggest that the immunostimulatory effect of LEN in ATC and the promising finding of clinical activity associated with this drug may be conferred by direct effects on circulating immune cells. It is noteworthy that the combination of LEN and PEM has been approved for the treatment of endometrial cancer and is under study in a broad spectrum of tumors (36). Markers of treatment response are yet to be discovered.

CONCLUSION
Our study of the expression of PD-L1 and FGFR 1-4 in ATC and PDTC supports the use of immune checkpoint inhibitors in the majority of ATC and some PDTC with high PD-L1 expression.
| Prognostic factors | Univariate analysis | Multivariate analysis |
|-------------------|---------------------|----------------------|
|                   | HR | 95% CI | P (log rank) | HR | 95% CI | P (cox regression) |
| **ATC**           |    |        |             |    |        |                  |
| **Pretreatment factors** |    |        |             |    |        |                  |
| **Sex**           |    |        |             |    |        |                  |
| Male (n=40)       |    |        |             |    |        |                  |
| Female (n=53)     |    |        |             |    |        |                  |
| **Age at diagnosis** (years) |    |        |             |    |        |                  |
| <69 (n=46)        | 1.689 | 1.091-2.614 | 0.017 | 1.724 | 0.958-3.104 | 0.069 |
| ≥69 (n=47)        | 1.091-2.614 | 0.017 | 1.724 | 0.958-3.104 | 0.069 |
| **UICC**          |    |        |             |    |        |                  |
| IVB (n=41)        |    |        |             |    |        |                  |
| IVC (n=48)        |    |        |             |    |        |                  |
| **PD-L1**         |    |        |             |    |        |                  |
| ≤5% (n=25)        | 1.886 | 1.200-2.966 | 0.005 | 2.068 | 1.244-3.438 | 0.005 |
| 5%-50% (n=29)     | 1.200-2.966 | 0.005 | 2.068 | 1.244-3.438 | 0.005 |
| ≥50% (n=39)       | 1.200-2.966 | 0.005 | 2.068 | 1.244-3.438 | 0.005 |
| **Complete local resection** |    |        |             |    |        |                  |
| Yes (n=11)        |    |        |             |    |        |                  |
| No (n=71)         |    |        |             |    |        |                  |
| **Treatment factors** |    |        |             |    |        |                  |
| **External beam radiation** |    |        |             |    |        |                  |
| No (n=14)         | 0.503 | 0.277-0.915 | 0.021 | 0.483 | 0.228-0.941 | 0.033 |
| Yes (n=79)        | 0.277-0.915 | 0.021 | 0.483 | 0.228-0.941 | 0.033 |
| **Chemotherapy**  |    |        |             |    |        |                  |
| No (n=43)         |    |        |             |    |        |                  |
| Yes (n=48)        | 0.619 | 0.399-0.962 | 0.031 | 0.582 | 0.335-1.011 | 0.055 |
| **PDTC**          |    |        |             |    |        |                  |
| **Pretreatment factors** |    |        |             |    |        |                  |
| **Sex**           |    |        |             |    |        |                  |
| Male (n=17)       |    |        |             |    |        |                  |
| Female (n=30)     |    |        |             |    |        |                  |
| **Age at diagnosis** (years) |    |        |             |    |        |                  |
| <63 (n=23)        | 3.176 | 1.002-10.060 | 0.04 | 2.984 | 0.907-9.819 | 0.072 |
| ≥63 (n=24)        | 1.002-10.060 | 0.04 | 2.984 | 0.907-9.819 | 0.072 |
| **UICC**          |    |        |             |    |        |                  |
| I, II and III (n=33) |    |        |             |    |        |                  |
| IVA and IVC (n=13) |    |        |             |    |        |                  |
| **PD-L1**         |    |        |             |    |        |                  |
| ≤5% (n=25)        | 0.496 |        |             |    |        |                  |
| 5%-50% (n=10)     | 0.496 |        |             |    |        |                  |
| ≥50% (n=12)       | 0.496 |        |             |    |        |                  |
| **Complete local resection** |    |        |             |    |        |                  |
| Yes (n=12)        |    |        |             |    |        |                  |
| No (n=25)         |    |        |             |    |        |                  |
| **Treatment factors** |    |        |             |    |        |                  |
| **Radioiodine treatment** |    |        |             |    |        |                  |
| No (n=11)         | 0.148 | 0.038-0.517 | 0.001 | 0.284 | 0.07-2.177 | 0.284 |
| Yes (n=36)        | 0.038-0.517 | 0.001 | 0.284 | 0.07-2.177 | 0.284 |
| **Radioiodine treatment** |    |        |             |    |        |                  |
| <6.65 GBq (n=18) | 4.065 | 1.180-14.001 | 0.016 | 2.55 | 0.512-12.702 | 0.253 |
| ≥6.65 GBq (n=18) | 1.180-14.001 | 0.016 | 2.55 | 0.512-12.702 | 0.253 |
| **External beam radiation** |    |        |             |    |        |                  |
| No (n=31)         | 4.291 | 1.050-17.537 | 0.027 | 1.779 | 0.367-8.626 | 0.475 |
| Yes (n=6)         | 1.050-17.537 | 0.027 | 1.779 | 0.367-8.626 | 0.475 |

*p-values of Bonferroni testing for pairwise comparisons between ATC and PDTC are indicated.*
although the role of PD-L1 expression for treatment decisions remains to be established. Tumoral FGFR expression is similarly low in ATC and PDTC and likely not the principal target of lenvatinib. In the light of the clinical response of ATC to combined LEN and immune checkpoint inhibitor treatment, we suggest a yet unknown tumoral LEN target or a LEN target not expressed in the tumor to be relevant for the clinically observed drug synergism. We propose to study peripheral immune cells and tumor infiltrating leukocytes systematically in clinical trials to identify markers of treatment response and better understand the mechanistic basis of combination therapy.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

MK, MF, CSp, CD, MS, and AZ designed the study. PA, SK, and IS performed experiments. SK, VK, EB, TK, BSa, WF, HB, CSm, AZ, BSi, SA, MS, CD, CSp, MF, and MK provided samples and data. PA and MK analyzed the data. PA, SK, VK, BSi, AZ, MF, and MK interpreted the data. PA and MK wrote a manuscript draft. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported – in part - by the Else Kröner Fresenius Stiftung, grant number 2016-A96.

ACKNOWLEDGMENTS

The authors wish to thank all patients, their families and caregivers for providing clinical data and tumor sections for this study. The authors thank Bianca Schlierf, Nathalie Schwenk, Martina Zink, Ramona Walter and Johanna Vogt for excellent technical support and Dr. Isabel Weigand for critical reading of the manuscript. This work has been carried out with the help of the Interdisciplinary Bank of Biomaterials and Data of the University Hospital of Würzburg and the Julius-Maximilians-University of Würzburg (IBDW) (37).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.712107/full#supplementary-material

Supplementary Figure 1 | Kaplan-Meier plots of DSS in patients according to PD-L1 expression. Disease specific survival of ATC (A) and PDTC (B) patients with TPS categories <50% and ≥50%. Supplementary Figure 2 | Kaplan-Meier plots of DSS in patients according to panFGFR expression. Disease specific survival of ATC (A) and PDTC (B) patients with mean panFGFR expression (2 mRNA/cell [ATC], 3 mRNA/cell [PDTC]).
13. Tumours WHOCo. "WHO Classification of Tumours of Endocrine Organs". In: RV Lloyd, RY Osamura, G Klöppel and J Rosai, editors. World Health Organization Classification of Tumours, 4th ed. Lyon: International Agency for Research on Cancer IARC (2017). p. 100–6.

14. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer. *N Engl J Med* (2015) 372(7):621–30. doi: 10.1056/NEJMoa1406470

15. Marotta V, Sciammarella C, Vitale M, Colao A, Faggiano A. The Evolving Field of Kinase Inhibitors in Thyroid Cancer. *Crit Rev Oncol Hematol* (2015) 93(1):60–73. doi: 10.1016/j.critrevonc.2014.08.007

16. Marotta V, Chiofalo MG, Di Gennaro F, Daponte A, Sandomenico F, Vallone P, et al. Kinase-Inhibitors for Iodine-Refractory Differentiated Thyroid Cancer: Still Far From a Structured Therapeutic Algorithm. *Crit Rev Oncol Hematol* (2021) 162:103353. doi: 10.1016/j.critrevonc.2021.103353

17. Iwasaki H, Toda S, Suganuma N, Murayama D, Nakayama H, Masudo K. Lenvatinib vs. Palliative Therapy for Stage IVC Anaplastic Thyroid Cancer. *Mol Clin Oncol* (2020) 12(2):138–43. doi: 10.3892/mco.2019.1964

18. Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshioka K, et al. Safety and Effectiveness of Lenvatinib in 594 Patients With Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. *Adv Ther* (2020) 37(9):3850–62. doi: 10.1002/adt.20213

19. Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells (2019) 8(6):614. doi: 10.3390/cells8060614

20. Yamazaki H, Yokose T, Hayashi H, Iwasaki H, Osanai S, Suganuma N, et al. Expression of Fibroblast Growth Factor Receptor 4 and Clinical Response to Lenvatinib in Patients With Anaplastic Thyroid Carcinoma: A Pilot Study. *Eur J Clin Pharmacol* (2020) 76(5):703–9. doi: 10.1007/s00228-019-02842-y

21. Stuhler V, Maas JM, Rausch S, Stenzl A, Bedke J. Immune Checkpoint Inhibition for the Treatment of Renal Cell Carcinoma. *Expert Opin Biol Ther* (2020) 20(1):93–100. doi: 10.1080/17460938.2019.1677601

22. Garon EB, Rizvi NA, Hui R, Leigh N, Balmanoukian AS, Edler JP, et al. Pembrolizumab for the Treatment of non-Small Cell Lung Cancer. *N Engl J Med* (2015) 372(21):2018–28. doi: 10.1056/NEJMoa1501824

23. Ferris RL, Licitira L. PD-1 Immunotherapy for Recurrent or Metastatic HNSCC. *Lancet* (2019) 394(10122):1882–4. doi: 10.1016/S0140-6736(19)32539-5

24. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol* (2019) Jco1901307:193–202. doi: 10.1200/JOCC.19.01307

25. Yu Y, Zeng D, Qu Q, Liu S, Li A, Chen Y, et al. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Individual-Patient-Level Analysis. *JAMA Netw Open* (2019) 2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879

26. Capdevilla J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. *J Clin Oncol* (2020) 38(23):2620–7. doi: 10.1200/JCO.20.02727

27. Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, et al. A Phase 2 Study of Pembrolizumab Combined With Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. *Thyroid* (2019) 29 (11):1615–22. doi: 10.1089/thy.2019.0086

28. Dierks C, Seuffert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. The Lenvatinib/Pembrolizumab Combination is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. *Thyroid* (2021) 31(7):1076–85. doi: 10.1089/thy.2020.0322

29. Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Matescu V, Sams SR, et al. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. *J Clin Endocrinol Metab* (2016) 101(7):2863–73. doi: 10.1210/jc.2015-4227

30. Zwanepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Sozopolou V, et al. CD70 and PD-L1 in Anaplastic Thyroid Cancer - Promising Targets for Immunotherapy. *Histopathology* (2017) 71(3):357–65. doi: 10.1111/his.13230

31. Fadia M, Fookereah P, Ali S, Shadbolt B, Greenaway T, Perampalam S. PD-L1 Expression in Papillary Thyroid Cancer With and Without Lymphocytic Thyroiditis: A Cross Sectional Study. *Pathology* (2020) 52(3):318–22. doi: 10.1016/j.pathol.2019.11.007

32. Girolami L, Pantanowitz L, Mete O, Brunelli M, Marletta S, Colato C, et al. Programmed Death-Ligand 1 (PD-1/L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis of PD-L1 Immunoeexpression in Follicular Epithelial Derived Thyroid Carcinoma. *Endocr Pathol* (2020) 31(3):291–300. doi: 10.1007/s12222-020-09630-5

33. Gunda V, Gligioti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, et al. Anti-PD-1/PD-L1 Therapy Augments Lenvatinib’s Efficacy by Favorably Altering the Immune Microenvironment of Murine Anaplastic Thyroid Cancer. *Int J Cancer* (2019) 144(9):2266–78. doi: 10.1002/ijc.32041

34. Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, et al. Preliminary Data of VEGF-A and VEGFR-2 Polymorphisms as Predictive Factors of Radiological Response and Clinical Outcome in Iodine-Refractory Differentiated Thyroid Cancer Treated With Sorafenib. *Endocrine* (2017) 57(3):539–43. doi: 10.1007/s12020-016-1200-6

35. Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, et al. Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. *J Clin Endocrinol Metab* (2019) 102(2):661–71. doi: 10.1210/jc.2016-2555

36. Hao Z, Wang P, Lenvatinib in Management of Solid Tumors. *Oncologist* (2020) 25(2):e302–e10. doi: 10.1634/theoncologist.2019-0407

37. Geiger J, Both S, Kircher S, Neumann M, Rosenwald A, Jahns R. Hospital-Integrated Biobanking as a Service – The Interdisciplinary Bank of Biomaterials and Data Wuerzburg (Ibdw). *Open J Bioreesour* (2018) 5:6. doi: 10.5334/ojbr.38

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.